SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun advances on receiving EIR from USFDA for its Oral Dosage facility at Bangalore

07 Jun 2016 Evaluate

Strides Shasun is currently trading at Rs. 1127.80, up by 9.50 points or 0.85% from its previous closing of Rs. 1118.30 on the BSE.

The scrip opened at Rs. 1118.00 and has touched a high and low of Rs. 1166.05 and Rs. 1108.00 respectively. So far 49,081 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 23-Nov-2015 and a 52 week low of Rs. 848.00 on 29-Feb-2016.

Last one week high and low of the scrip stood at Rs. 1166.05 and Rs. 1095.00 respectively. The current market cap of the company is Rs. 10,084.00 crore.

The promoters holding in the company stood at 31.14% while Institutions and Non-Institutions held 46.98% and 21.88% respectively.

Strides Shasun’s Oral Dosage Forms manufacturing site (KRS Gardens) in Bangalore which was inspected by the USFDA in February 2016 has received the Establishment Inspection Report (EIR), thereby confirming the closure of the inspection. The facility continues to be USFDA approved.

The KRS Gardens facility in Bangalore manufactures oral dosage forms including tablets, capsules (both hard gelatine and soft gelatine). The manufacturing plant supports important current and future submissions for the US Market.

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and and semi-solids.


Strides Pharma Scien Share Price

999.55 3.65 (0.37%)
21-Apr-2026 12:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.00
Dr. Reddys Lab 1221.00
Cipla 1232.00
Zydus Lifesciences 927.00
Lupin 2321.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×